Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance

Journal of Immunology Research

Volumn 2016, Issue , 2016, Pages

  Song, Sam ^a   Yang, Lili ^a   Trepicchio, William L ^a   Wyant, Timothy ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; HYBRID PROTEIN; MONOCLONAL ANTIBODY; ANTIBODY; BIOLOGICAL PRODUCT; DRUG;

ANTIBODY SCREENING; ANTIGEN ANTIBODY COMPLEX; DRUG ANTIBODY ASSAY; DRUG COMPETITION; DRUG SAFETY; DRUG TOLERANCE; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; PATIENT SAFETY; QUANTITATIVE ASSAY; REVIEW; SENSITIVITY ANALYSIS; BLOOD; IMMUNOLOGY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ANTIBODIES; BIOLOGICAL PRODUCTS; HUMANS; IMMUNOASSAY; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84975317276     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2016/3072586     Document Type: Review

References (39)

1. I. N. Foltz, M. Karow, and S. M. Wasserman, "Evolution and emergence of therapeutic monoclonal antibodies what cardiologists need to know, " Circulation, vol. 127, no. 22, pp. 2222-2230, 2013.
2. G. Shankar, C. Pendley, and K. E. Stein, "Arisk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs, " Nature Biotechnology, vol. 25, no. 5, pp. 555-561, 2007.
3. N. Chirmule, V. Jawa, and B. Meibohm, "Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy, "The AAPS Journal, vol. 14, no. 2, pp. 296-302, 2012.
4. C. Hay, M. Recht, M. Carcao, and B. Reipert, "Current and future approaches to inhibitormanagement and aversion, " Seminars in Thrombosis and Hemostasis, vol. 32, no. 2, pp. 15-21, 2006.
5. P. G. Swann, M. Tolnay, S. Muthukkumar, M. A. Shapiro, B. L. Rellahan, and K. A. Clouse, "Considerations for the development of therapeutic monoclonal antibodies, " Current Opinion in Immunology, vol. 20, no. 4, pp. 493-499, 2008.
6. R. Thorpe and S. J. Swanson, "Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures, " Nephrology Dialysis Transplantation, vol. 20, no. 4, pp. 16-22, 2005.
7. W. Y. K. Hwang and J. Foote, "Immunogenicity of engineered antibodies, " Methods, vol. 36, no. 1, pp. 3-10, 2005.
8. R. Ponce, L. Abad, L. Amaravadi et al., "Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies, " Regulatory Toxicology and Pharmacology, vol. 54, no. 2, pp. 164-182, 2009.
9. M. Wadhwaa, C. Birda, P. Dilgera, R. Gaines-Dasb, and R. Thorpea, "Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biological, " Journal of Immunological Methods, vol. 278, no. 1-2, pp. 1-17, 2003.
10. K. E. Stein, "Immunogenicity: concepts/issues/concerns, " Developments in Biologicals, vol. 109, pp. 15-23, 2002.
11. F. Baert, M. Noman, S. Vermeire et al., "Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease, " The New England Journal of Medicine, vol. 348, no. 7, pp. 601-608, 2003.
12. G. M. Bartelds, C. L. M. Krieckaert, M. T. Nurmohamed et al., "Development of antidrug antibodies against Adalimumab and association with disease activity and treatment failure during long-term follow-up, " The Journal of the American Medical Association, vol. 305, no. 14, pp. 1460-1468, 2011.
13. B. A. Baldo, "Adverse events to monoclonal antibodies used for cancer therapy focus on hypersensitivity responses, " OncoImmunology, vol. 2, no. 10, article e26333, 2013.
14. K.-U. Eckardt and N. Casadevall, "Pure red-cell aplasia due to anti-erythropoietin antibodies, " Nephrology Dialysis Transplantation, vol. 18, no. 5, pp. 865-869, 2003.
15. A. R. Mire-Sluis, Y. C. Barrett, V. Devanarayan et al., "Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products, " Journal of Immunological Methods, vol. 289, no. 1-2, pp. 1-16, 2004.
16. G. Shankar, V. Devanarayan, L. Amaravadi et al., "Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products, " Journal of Pharmaceutical and Biomedical Analysis, vol. 48, no. 5, pp. 1267-1281, 2008.
17. US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research, Draft Guidance for Industry. Assay Development for Immunogenicity Testing of Therapeutic Proteins, 2009, http://www. fda. gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm338856. pdf.
18. US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research, "Guidance for industry, Immunogenicity assessment for therapeutic protein products, " 2014, http://www. fda. gov/downloads/%20drugs/guidancecomplianceregulatoryinformation/ guidances/ucm338856. pdf.
19. European Medicines Agency, Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In Vivo Clinical Use, European Medicines Agency, London, UK, 2012.
20. European Medicines Agency, "Guideline on Immunogenicity assessment of biotechnology-derived therapeutic proteins (Draft), " 2015, http://www. ema. europa. eu/docs/en GB/document library/Scientific guideline/2015/10/WC500194507. pdf.
21. US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research, "Draft guidance for industry. Assay development and validation for immunogenicity testing of therapeutic proteins, Revision 1, " 2016, http://www. fda. gov/ucm/ groups/fdagov-public/@fdagov-drugs-gen/documents/document/ ucm192750. pdf.
22. Y.-M. C. Wang, L. Fang, L. Zhou, J. Wang, and H.-Y. Ahn, "A survey of applications of biological products for drug interference of immunogenicity assays, " Pharmaceutical Research, vol. 29, no. 12, pp. 3384-3392, 2012.
23. AbbVie: Humira Insert, 2013, http://www. accessdata. fda. gov/ drugsatfda docs/label/2013/125057s310lbl. pdf.
24. A. Patton, M. C. Mullenix, S. J. Swanson, and E. Koren, "An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen, " Journal of Immunological Methods, vol. 304, no. 1-2, pp. 189-195, 2005.
25. H. W. Smith, A. Butterfield, and D. Sun, "Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA, " Regulatory Toxicology and Pharmacology, vol. 49, no. 3, pp. 230-237, 2007.
26. Meso ScaleDiscovery, "ImmunogenicityAssay fromMeso Scale Discovery, " 2012, http://www. mesoscale. com/.
27. Meso Scale Discovery, MSD Technology Platform, 2013, http:// www. mesoscale. com.
28. Gyros, "Automated immunoassays at nanoliter-scale, " 2016, http://www. gyros. com/why-gyros/technology/.
29. Genalyte, "Detection of isotype and IgG subclass anti-adalimumab antibodies with a multiplex photonic ring immunoassay, " 2014, http://www. info@genalyte. com.
30. M. H. Hart, H. de Vrieze, D. Wouters et al., "Differential effect of drug interference in immunogenicity assays, " Journal of Immunological Methods, vol. 372, no. 1-2, pp. 196-203, 2011.
31. S. Dai, A. Schantz, A. Clements-Egan, M. Cannon, and G. Shankar, "Development of a method that eliminates falsepositive results due to nerve growth factor interference in the assessment of fulranumab immunogenicity, " AAPS Journal, vol. 16, no. 3, pp. 464-477, 2014.
32. L. Zou, "Overcome drug and soluble target interferences in immunogenicity sample analysis for antibody therapy, " in Proceedings of the IBC's 16th Annual Immunogenicity for Biotherapeutics, Reston, Va, USA, 2015.
33. G. Shankar, S. Arkin, L. Cocea et al., "Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations, " The AAPS Journal, vol. 16, no. 4, pp. 658-673, 2014.
34. L. Amaravadi, A. Song, H. Myler et al., "2015 White paper on recent issues in bioanalysis: focus on new technologies and biomarkers (part 3-LBA, biomarkers and immunogenicity), " Bioanalysis, vol. 7, no. 24, pp. 3107-3124, 2015.
35. A. Vennegoor, T. Rispens, E. M. M. Strijbis et al., "Clinical relevance of serum natalizumab concentration and antinatalizumab antibodies in multiple sclerosis, " Multiple Sclerosis Journal, vol. 19, no. 5, pp. 593-600, 2013.
36. P. A. Calabresi, G. Giovannoni, C. Confavreux et al., "The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL, " Neurology, vol. 69, no. 14, pp. 1391-1403, 2007.
37. B. Oliver, O. Fernández, T. Orpez et al., "Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months, " Multiple Sclerosis, vol. 17, no. 3, pp. 368-371, 2011.
38. P. S. Sørensen, P. E. Hyldgaard Jensen, A. Haghikia et al., "Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab, " Multiple Sclerosis Journal, vol. 17, no. 9, pp. 1074-1078, 2011.
39. Biogen Idec and élan, Tysabri Insert, 2013, http://www. fda. gov/ safety/medwatch/safetyinformation/%20safety-relateddruglabelingchanges% 20/ucm106674. htm.